Literature DB >> 6427329

Differential expression of cell activation markers after stimulation of resting human B lymphocytes.

J H Kehrl, A Muraguchi, A S Fauci.   

Abstract

The interaction of antigen with surface Ig receptors initiates a complex process by which resting B lymphocytes are activated. In this study, small resting B lymphocytes were isolated by countercurrent elutriation of tonsillar B lymphocytes and stimulated with a range of concentrations of anti-mu and B cell growth factor (BCGF). The subsequent expression of two glycoproteins known to be absent from resting B lymphocytes but present on activated cells were analyzed with the monoclonal antibodies 4F2 and 5E9. The antigen recognized by the 4F2 monoclonal was expressed early in the G1 phase of the cell cycle and correlated with blast transformation; this was demonstrated by stimulating resting B cells with a low concentration of anti-mu sufficient for cellular activation but not proliferation. The 5E9-defined antigen was not present unless the B cells were stimulated with a higher concentration of anti-mu or a BCGF was added to the low concentration of anti-mu. The addition of hydroxyurea to culture blocked the entrance of stimulated B cells into S phase but did not interfere with the expression of either 4F2 or 5E9. Thus, whereas the monoclonal antibody 4F2 recognized cells in early G1, 5E9 recognized cells in late G1. By double immunofluorescence staining with propidium iodide and either 4F2 or 5E9, all cells in S, G2, and M phases were demonstrated to be both 4F2- and 5E9-positive. The monoclonal antibodies 4F2 and 5E9 can be used to distinguish an activated from a resting human B lymphocyte and to delineate sequential steps in the activation process.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6427329

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen.

Authors:  M Papetti; I M Herman
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 2.  Membrane Ig-mediated triggering of B cell tolerance and B cell clonal expansion: implications for rheumatoid factor production in rheumatoid synovitis.

Authors:  P K Mongini; S M Rudich
Journal:  Springer Semin Immunopathol       Date:  1989

3.  Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.

Authors:  F A Karlsson; T H Tötterman
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

4.  Memory B lymphocytes migrate to bone marrow in humans.

Authors:  E Paramithiotis; M D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

5.  Pathways of human B-lymphocyte activation blocked by B-cell specific monoclonal antibodies.

Authors:  J T Golay; D H Crawford
Journal:  Immunology       Date:  1987-10       Impact factor: 7.397

6.  Normal human intestinal B lymphocytes. Increased activation compared with peripheral blood.

Authors:  M G Peters; H Secrist; K R Anders; G S Nash; S R Rich; R P MacDermott
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

7.  Isolation and structural characterization of the human 4F2 heavy-chain gene, an inducible gene involved in T-lymphocyte activation.

Authors:  K M Gottesdiener; B A Karpinski; T Lindsten; J L Strominger; N H Jones; C B Thompson; J M Leiden
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

8.  Immunomodulatory effect of fosfomycin on human B-lymphocyte function.

Authors:  K Morikawa; F Oseko; S Morikawa
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 9.  The role of CD98 in astrocytic neoplasms.

Authors:  Hiroshi Nawashiro; Naoki Otani; Nariyoshi Shinomiya; Shinji Fukui; Namiko Nomura; Akiko Yano; Katsuji Shima; Hirotaka Matsuo; Yoshikatsu Kanai
Journal:  Hum Cell       Date:  2002-03       Impact factor: 4.174

10.  Increased in vitro release of soluble interleukin 2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease.

Authors:  S Schreiber; A Raedler; A R Conn; J L Rombeau; R P MacDermott
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.